 Together, these data indicate that treatment emergent diabetes, along with other metabolic disturbances e.g., dyslipidemia and obesity, represents a serious issue in the use of atypical antipsychotics. This notwithstanding, many questions of crucial clinical and theoretical interest remain un-clarified. Major current debates and unresolved research issues include: 